ClinicalTrials.gg
CompletedNCT00192075Updated Feb 7, 2011Results posted

A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer

A Phase 2 interventional study of Gemcitabine and avastin in Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-07.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing gemcitabine in Colorectal Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Gemcitabine · Colorectal Neoplasms.

Enrollment
4th of 19
84 · median 49
Started
2003
the only one that year
Phase 2
12 of 19
1 open now
Registered
7th of 19
by date
Lead sponsor
1 of 19
Eli Lilly and Company

Among the 19 studies testing gemcitabine in Colorectal Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2003, is one of 12 in phase 2, and was the 7th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 19 studies testing gemcitabine in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing gemcitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease after they receive treatment, and how long the response they get from the treatment lasts. The amount and type of side effects/toxicities of each regimen will also be evaluated. The regimen including Oxaliplatin + 5FU/Folinic Acid is a current standard of care.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a histological or cytological diagnosis of the colon or rectum with Stage III unresectable or Stage IV disease.
  • Urinalysis or Urine dipstick for proteinuria of less than 1+ (i.e. either 0 or trace). If urine dipstick is greater than 1+, the 24 hour urine protein must demonstrate less than 500 mg of protein in 24 hours to allow participation.
  • No prior chemotherapy, immunotherapy, or hormonal treatment for disease is acceptable. However, one prior or adjuvant treatment is acceptable, including Capecitabine, Camptothecin-11 (CPT-11), 5 Fluorouracil/Leucovorin (5FU/LV) or Radiation containing regimens, (but no Oxaliplatin), and only if progression > 6 months since last adjuvant treatment.
  • Prior radiation therapy, including radiation to the whole pelvis, is allowed (Cristy and Eckerman 1987) and patients must have recovered from the acute toxic effects of the treatment prior to study enrollment. Prior palliative radiation therapy given to a non-measurable diagnostic site is acceptable if given > 4 weeks prior to treatment or if other non-irradiated is present.
  • No known central nervous system (CNS) metastasis.

Exclusion criteria

Exclusion Criteria:

  • Histology other than adenocarcinoma
  • Tumors that demonstrate free perforation as manifested by free air or free fluid in the abdomen. Patients with walled-off perforation are eligible.
  • Gastroduodenal ulcer determined as active by endoscopy.
  • Invasive procedures defined as follows; major surgical procedures, open , or significant traumatic injury within 28 days prior to randomization, anticipation of need for major surgical procedure during the course of study, core biopsy or other minor procedure within 7 days prior to registration.
  • Following cardiac condition; (NYHA) Class III or IV, myocardial infarction (MI) within 6 months, unstable angina within 6 months and current symptomatic arrhythmia.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    A+FFG

    Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid

    Drug: Gemcitabine · Drug: avastin · Drug: 5FU/folinic acid

  • Active comparator
    A+FOLFOX 4

    Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid

    Drug: avastin · Drug: 5FU/folinic acid · Drug: oxaliplatin

Interventions

  • 900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.

    Also known as: Gemzar

  • 5 milligrams per kilogram (mg/kg)

  • Drug5FU/folinic acid

    Drug pages: Fluorouracil · Leucovorin

    Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG). Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4). 5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).

  • 85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.

06

What researchers measure

Primary outcomes

  1. Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Secondary outcomes

  1. Time to Progressive Disease

    Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

    Time frame: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  2. Progression-Free Survival

    Defined as the time from randomization to the first observation of disease progression, or death due to any cause.

    Time frame: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  3. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  4. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Other outcomes

  1. Tumor Response - Avastin Subgroup

    Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  2. Time to Progressive Disease - Avastin Subgroup

    Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

    Time frame: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  3. Progression-Free Survival - Avastin Subgroup

    Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.

    Time frame: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  4. Survival at 12 Months and 24 Months - Avastin Subgroup

    Percentage of participants who were alive at 12 months and 24 months.

    Time frame: randomization to the date of death from any cause (up to 24 months)

  5. Toxicity - Avastin Subgroup

    Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either \>=1 Grade 4 or \>=2 Grade 3 adverse events

    Time frame: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

  6. Duration of Response - A+FOLFOX4 - Avastin Subgroup

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

07

Results

Posted Dec 23, 2009

Participant flow

Participant flow — Overall Study
MilestoneA+FFGA + FOLFOX 4
Started4242
Completed323
Not completed3919
Withdrew: Disease progression236
Withdrew: Adverse event13
Withdrew: Death01
Withdrew: Lack of efficacy00
Withdrew: Physician decision30
Withdrew: Withdrawal by subject55
Withdrew: Patient non-compliance01
Withdrew: Unacceptable toxicity exhibited by drug21
Withdrew: Other52

Outcome measures

PrimaryTumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Number · participants
Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)
participantsA+FFGA + FOLFOX 4
Complete Response (CR)12
Partial Response (PR)315
Overall Response Rate (CR+PR)417
Stable Disease (SD)2116
Disease Control Rate (CR+PR+SD)2533
Progressive Disease147
Unknown32
SecondaryTime to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

Time frame:
randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Time to Progressive Disease
monthsA+FFGA + FOLFOX 4
Time to Progressive Disease8.6 (5.3 to 17.9)9.7 (7.3 to 11.2)
SecondaryProgression-Free Survival

Defined as the time from randomization to the first observation of disease progression, or death due to any cause.

Time frame:
randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Progression-Free Survival
monthsA+FFGA + FOLFOX 4
Progression-Free Survival8.6 (4.7 to 17.9)9.5 (6.9 to 11.2)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Overall Survival
monthsA+FFGA + FOLFOX 4
Overall Survival20.6 (14.8 to 26.7)19.7 (11.2 to 32.0)
Other pre-specifiedTumor Response - Avastin Subgroup

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Number · participants
Tumor Response - Avastin Subgroup
participantsA+FFG - Avastin SubgroupA + FOLFOX 4 - Avastin Subgroup
Complete Response (CR)01
Partial Response (PR)08
Overall Response Rate (CR+PR)09
Stable Disease (SD)118
Disease Control Rate (CR+PR+SD)1117
Progressive Disease61
Unknown10
Other pre-specifiedTime to Progressive Disease - Avastin Subgroup

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

Time frame:
randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Time to Progressive Disease - Avastin Subgroup
monthsA+FFG - Avastin SubgroupA + FOLFOX 4 - Avastin Subgroup
Time to Progressive Disease - Avastin Subgroup13.7 (4.6 to 19.3)13.8 (6.3 to 23.7)
Other pre-specifiedProgression-Free Survival - Avastin Subgroup

Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause.

Time frame:
randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Progression-Free Survival - Avastin Subgroup
monthsA+FFG - Avastin SubgroupA + FOLFOX 4 - Avastin Subgroup
Progression-Free Survival - Avastin Subgroup13.7 (4.6 to 19.3)11.5 (6.3 to 18.1)
Other pre-specifiedSurvival at 12 Months and 24 Months - Avastin Subgroup

Percentage of participants who were alive at 12 months and 24 months.

Time frame:
randomization to the date of death from any cause (up to 24 months)
Reported as:
Number · percentage of participants alive
Survival at 12 Months and 24 Months - Avastin Subgroup
percentage of participants aliveA+FFG - Avastin SubgroupA + FOLFOX 4 - Avastin Subgroup
12-Month Survival75.6 (47.3 to 90.1)83.3 (56.8 to 94.3)
24-Month Survival50.4 (24.9 to 71.4)66.7 (40.4 to 83.4)
Other pre-specifiedToxicity - Avastin Subgroup

Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either \>=1 Grade 4 or \>=2 Grade 3 adverse events

Time frame:
every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Number · participants
Toxicity - Avastin Subgroup
participantsA+FFG - Avastin SubgrouupA + FOLFOX 4 - Avastin Subgroup
Neutropenia (Grade 3)35
Neutropenia (Grade 4)51
Thrombocytopenia (Grade 3)10
Thrombocytopenia (Grade 4)00
Leukopenia (Grade 3)30
Leukopenia (Grade 4)10
Anemia (Grade 3)00
Anemia (Grade 4)00
Febrile neutropenia (Grade 3)01
Febrile neutropenia (Grade 4)00
Diarrhea (Grade 3)10
Diarrhea (Grade 4)01
Small intestinal obstruction (Grade 3)11
Small intestinal obstruction (Grade 4)00
Fatigue (Grade 3)02
Fatigue (Grade 4)00
Cerebral infarction (Grade 3)00
Cerebral infarction (Grade 4)00
Hyperglycemia (Grade 3)00
Hyperglycemia (Grade 4)00
Dehydration (Grade 3)01
Dehydration (Grade 4)00
Deep vein thrombosis (Grade 3)02
Deep vein thrombosis (Grade 4)00
Myocardial infarction (Grade 3)00
Myocardial infarction (Grade 4)02
Subdural hematoma (Grade 3)00
Subdural hematoma (Grade 4)00
Perirectal abscess (Grade 3)10
Perirectal abscess (Grade 4)00
Hypoxia (Grade 3)00
Hypoxia (Grade 4)00
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Duration of Response
monthsA+FFGA + FOLFOX 4
Duration of Response12.7 (5.5 to 32.9)7.9 (4.4 to 9.8)
Other pre-specifiedDuration of Response - A+FOLFOX4 - Avastin Subgroup

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
Reported as:
Median · months
Duration of Response - A+FOLFOX4 - Avastin Subgroup
monthsA + FOLFOX 4 - Avastin Subgroup
Duration of Response - A+FOLFOX4 - Avastin Subgroup5.2 (4.2 to 13.8)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A+FFG—11/42 (26.2%)40/42 (95.2%)
A + FOLFOX 4—8/42 (19%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventA+FFGA + FOLFOX 4
NeutropeniaBlood and lymphatic system disorders0/422/42
Myocardial infarctionCardiac disorders0/422/42
Small intestinal obstructionGastrointestinal disorders1/422/42
Urinary tract infectionInfections and infestations0/422/42
PalpitationsCardiac disorders1/420/42
ConstipationGastrointestinal disorders0/421/42
DiarrhoeaGastrointestinal disorders1/421/42
EnteritisGastrointestinal disorders1/420/42
Gastrointestinal haemorrhageGastrointestinal disorders0/421/42
Perirectal abscessGastrointestinal disorders1/421/42
Most frequent other events
Showing 10 of 58
Most frequent other events
EventA+FFGA + FOLFOX 4
NauseaGastrointestinal disorders19/4225/42
NeutropeniaBlood and lymphatic system disorders24/4216/42
FatigueGeneral disorders22/4224/42
DiarrhoeaGastrointestinal disorders15/4217/42
AnaemiaBlood and lymphatic system disorders16/424/42
ConstipationGastrointestinal disorders15/4210/42
VomitingGastrointestinal disorders8/4215/42
ThrombocytopeniaBlood and lymphatic system disorders14/428/42
ParaesthesiaNervous system disorders2/4211/42
PyrexiaGeneral disorders10/426/42

Baseline characteristics

Age Continuous
Age Continuous(years)A+FFGA + FOLFOX 4Total
Median62 (28 to 79)64 (32 to 81)63 (28 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)A+FFGA + FOLFOX 4Total
Female212243
Male212041
Region of Enrollment
Region of Enrollment(participants)A+FFGA + FOLFOX 4Total
United States424284
Diagnosis to Enrollment
Diagnosis to Enrollment(participants)A+FFGA + FOLFOX 4Total
<6 months292958
>=6 months131326
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)A+FFGA + FOLFOX 4Total
0 - Fully Active232043
1 - Ambulatory, Restricted Strenuous Activity192241
Primary Tumor Site
Primary Tumor Site(participants)A+FFGA + FOLFOX 4Total
Colon253560
Rectum10414
Other7310
Prior Adjuvant Therapy
Prior Adjuvant Therapy(participants)A+FFGA + FOLFOX 4Total
Yes121426
No302858
Race/Ethnicity
Race/Ethnicity(participants)A+FFGA + FOLFOX 4Total
Caucasian333467
African descent5611
Asian011
Hispanic415

2 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucson, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beverly Hills, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palm Springs, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stockton, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kansas City, Kansas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Massachusetts, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lansing, Michigan, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tupelo, Mississippi, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bronx, New York, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stonybrook, New York, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Burlington, North Carolina, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cincinnati, Ohio, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Ohio, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marshfield, Wisconsin, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L, Nicol SJ. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs. 2012 Apr;30(2):772-8. doi: 10.1007/s10637-010-9598-9. Epub 2010 Dec 1. PubMed 21120580 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Jun 2003
CompletionActual
Nov 2007
Results first posted
Dec 23, 2009
Last update
Feb 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00192075
First posted
Sep 19, 2005
Start date
Jun 2003
Completion
Nov 2007
Results posted
Dec 23, 2009
Last update
Feb 7, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion